Pune: Serum Institute Will Begin Production Of Sputnik V Vaccine From September

Serum Institute Of India Seeks DCGI’s Permission To Manufacture Sputnik V
Share this News:

Mrunal Jadhav

Pune, 13 July 2021: The Serum Institute of India (SII), based in Pune, will start the production of the Russian made Covid vaccine called Sputnik V in September.

 The Drug Controller General of India (DCGI) has approved the emergency use of the Sputnik V vaccine.

The first batch of the Sputnik V vaccine is expected to be produced in September 2021. Adar Poonawalla, CEO, Serum Institute of India informed about this.

“We are pleased to partner with RDIF (Russian Direct Investment Fund) to produce the Sputnik V vaccine. We expect to produce millions of doses of the Sputnik V vaccine in the coming months. Trial batch will start in September”, said Poonawalla.

“The Sputnik V vaccine should be made available to citizens around the world, including India, for greater effectiveness and better safety. Given the uncertainty surrounding the virus, it is important for international organizations and governments to co-operate in the fight against coronavirus,” Poonawalla said.

The Sputnik V vaccine is claimed to be 91.6 per cent effective.

Adding further he said that RDIF’s Kiril Dimitrov has also played a role in this regard and is pleased to partner with the Serum Institute, the world’s largest vaccine manufacturer. This is a strategic partnership and will be an important step towards increasing production capacity.

In August, Russia announced it had made the first Vaccine against Covid-19 in the world. The announcement was made by Russian President Vladimir Putin. The vaccine was named Sputnik V. Sputnik V is also the name of a Russian satellite.

Join our WhatsApp GroupTelegram, and Twitter for every update about Pune and PCMC